02853nas a2200301   4500008004100000020001400041024001900055245011300074210006900187260012500256300001300381490000700394520180900401653004802210653005702258653001502315653001102330653001102341653000902352653001602361100002002377700002302397700001702420700002202437700002402459700002302483856004502506       2006                        eng d  a1527-6465  adk0, 10090918500aImmune thrombocytopenic purpura following liver transplantation: a case series and review of the literature.0 aImmune thrombocytopenic purpura following liver transplantation   aUnited StatesbTaylor,Ryan M. Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109-0362, USA.c2006  a781 - 910 v123 aThrombocytopenia is common among liver transplant candidates and recipients. The aim of our study was to determine the incidence and outcome of new-onset immune-mediated thrombocytopenic purpura (ITP) following liver transplantation at a single center. Among the 256 liver transplant recipients with an International Classification of Diseases, Ninth Edition code for thrombocytopenia, 8 cases of new-onset ITP were identified, leading to an overall incidence of 0.7% in 1,105 consecutive liver transplant recipients over a 15-year period. All 8 patients were Caucasian, 5 (63%) were male, and the median age at ITP onset was 54 years (range, 15-63). The median platelet count at presentation was 3,500 cells/mL (range, 1,000-12,000) and liver disease was due to hepatitis C (38%), primary sclerosing cholangitis (38%), and cryptogenic cirrhosis (25%). The median time from transplant to ITP onset was 53.5 months (range, 1.9-173). Three of the 6 patients tested (50%) had cell-bound antiplatelet antibodies, 1 patient had an underlying hematological malignancy, and none of the organ donors had a history of ITP. Corticosteroids and/or immunoglobulin infusions were effective in 4 patients. However, serial rituximab infusions were required in 4 patients with persistent thrombocytopenia, and 3 of them eventually required splenectomy to induce disease remission. At a median follow-up of 19.7 months, 7 long-term survivors remain in remission with a median platelet count of 267,000 cells/mL. In conclusion, new-onset ITP is an infrequent but important cause of severe thrombocytopenia in liver transplant recipients. Corticosteroids and immunoglobulin infusions were effective in 50% while the remainder of patients required rituximab infusions or eventual splenectomy for long-term disease remission.10a*Liver Transplantation/ae [Adverse Effects]10a*Purpura, Thrombocytopenic, Idiopathic/et [Etiology]10aAdolescent10aFemale10aHumans10aMale10aMiddle Aged1 aTaylor, Ryan, M1 aBockenstedt, Paula1 aSu, Grace, L1 aMarrero, Jorge, A1 aPellitier, Shawn, M1 aFontana, Robert, J  uhttp://613633.bywedr.asia/reference/4144